Agenda

Thursday, August 10, 2017

8:00 - 8:45 AM

Registration Check-in & Networking Breakfast

8:45 - 9:00 AM

Welcome & Retinal Innovation Highlights

Emmett T. Cunningham Jr., MD, PhD, MPH, Managing Director - Clarus Funds

9:00 - 9:35 AM

Retina Public Company Showcase

Moderated By:
Cal Roberts, MD, SVP, Chief Medical Officer - Bausch + Lomb

9:35 - 10:10 AM

Retina Private Company Showcase

Moderated By:
Namrata Saroj, OD, Executive Director, Ophthalmology Medical Affairs - Regeneron Pharmaceuticals

10:10 - 10:31 AM

Retinal Imaging 2017: Improved Trials Through Improved Imaging

Moderated By:
Jason Ehrlich, MD, PhD, Senior Group Medical Director - Genentech

Detection of apoptosing retinal cells (DARC) - a new retinal imaging biomarker

M. Francesca Cordeiro, MD, PhD - Professor - UCL and Imperial College London, Wester Eye Hospital London

Use of OCTA in AMD clinical trials

Andre Witkin, MD, Assistant Professor - Tufts University School of Medicine

Use of OCT and OCTA in Diabetic Retinopathy clinical trials

Amir H. Kashani, MD, PhD, Assistant Professor of Clinical Ophthalmology - USC Roski Eye Institute, Keck Medicine of USC

10:31 - 11:10 AM

AM Networking & Refreshment Break

11:10 - 11:20 AM

Public Market Trends in Ophthalmology

Andrew Gitkin, Head of West Coast Biotechnology Investment Banking - Piper Jaffray

11:20 - 12:00 PM

Seed Stage Financing

Moderated By:
Ali Behbahani, MD, Partner - NEA

Participants:
Mark S. Blumenkranz, MD, MMS, Chairman & Managing Director - Lagunita Biosciences
Angela Macfarlane, President & CEO - ForSight Labs
Firas M. Rahhal, MD, Partner - ExSight Ventures
Christy Shaffer, PhD, General Partner - Hatteras Venture Partners

12:00 - 12:40 PM

Networking Lunch

12:40 - 1:00 PM

OIS Lifetime Innovator Award

Award Recipient:
Mark S. Blumenkranz, MD, MMS, Chairman & Managing Director - Lagunita Biosciences
HJ Smead Professor Emeritus & Director of the Ophthalmic Innovation Program - Byers Eye Institute, Stanford

Interview Conducted By:
Emmett T. Cunningham Jr., MD, PhD, MPH, Managing Director - Clarus Funds

1:00 - 1:35 PM

Combination Therapy in AMD and DME

Moderated By:
Mark S. Humayun, MD, PhD, Professor of Ophthalmology - University of Southern California

Company Presentations:
Roche/Genentech | Charles Wykoff, MD, PhD, FACS
Regeneron | David Boyer, MD
Opthea Limited | Megan Baldwin, PhD, CEO & Managing Director
Allegro Ophthalmics | Vicken Karageozian, MD, President & Chief Medical Officer

Panel Discussion:
David Brown, MD, Director of Clinical Research - Retina Consultants of Houston
Pravin Dugel, MD, Managing Partner - Retinal Consultants of Arizona
Jeffrey Heier, MD, Co-President & Medical Director - Ophthalmic Consultants of Boston

1:35 - 2:10 PM

Retinal Drug Delivery

Moderated By:
John Pollack, MD, Partner - Illinois Retina Associates

Company Presentations:
Clearside Biomedical | Daniel White, President & CEO
Graybug Vision | Jeff Cleland, PhD, President & CEO
Ocular Therapeutix | Amar Sawhney, PhD, Executive Chairman
Genentech/ForSight VISION 4 | John Pollack, MD

Panel Discussion:
Szilárd Kiss, MD, Director, Clinical Research & Chief, Retina Service - Weill Cornell Medical College
David Boyer, MD, Retina-Vitreous Associates Medical Group
J. Michael Jumper, MD, Partner - West Coast Retina Medical Group

2:10 - 2:45 PM

PM Networking & Refreshment Break

2:45 - 3:20 PM

Gene and Cell Therapy

Company Presentations:
REGENXBIO | Stephen Yoo, MD, Chief Medical Officer
GenSight Biologics | Mohamed Genead, MD, Chief Medical Officer
BioTime | Oscar Cuzzani, MD, PhD, VP of Clinical Development

Panel Discussion:
Thomas Ciulla, MD, Volunteer Clinical Professor of Ophthalmology - Indiana University School of Medicine
Lucian Del Priore, MD, PhD, Professor & Chair of the Department of Ophthalmology & Visual Science - Yale University School of Medicine
Joel Naor, MD, VP Clinical Science & Development Operations - Kodiak Sciences
Steven Schwartz, MD, Ahmanson Professor of Ophthalmology, Retina Division Chief - Stein Eye Institute, UCLA

3:20 - 3:55 PM

Corporate Retina: Future Directions

Moderated By:
Gilbert H. Kliman, MD, Managing Director - InterWest Partners

Participants:
C. David Nicholson, PhD, Chief R&D Officer - Allergan
Angelo Rago, Head of Ophthalmic Diagnostics - Carl Zeiss Meditec
Dirk Sauer, PhD, Global Development Unit Head, Ophthalmology Unit - Novartis Pharma AG
Naveed Shams, MD, PhD, Sr. Corporate Officer, Head, Global R&D and Chief Science Officer - Santen Pharmaceuticals Ltd.
Carl Romano, PhD, Executive Director & Head of Ophthalmology Research - Regeneron Pharmaceuticals
Jason Ehrlich, MD, PhD, Senior Group Medical Director - Genentech